Importance of pharmacokinetic studies on cyclophosphamide (NSC-26271) in understanding its cytotoxic effect.
Pharmacokinetic studies on cyclophosphamide (CP) and its alkylating metabolites produced by hepatic biotransformation have been performed in vivo in animals and in vitro in the perfused liver. CP levels were determined by a gas-chromatographic method combined with mass-spectrometry, and production of alkylating metabolites was assayed by the 4-(4-nitrobenzyl)pyridine reaction for alkylating compounds. Differenes in serum drug levels between normal rats and rats bearing Walker 256 carcinosarcoma were observed in vivo and were confirmed by the liver-perfusion technique. Pharmacokinetic parameters and enzyme kinetic data both in normal and in tumor-bearing animals will be presented. The disappearance of CP and the corresponding formation of CP metabolites was significantly modified when (a) CP was given after previous treatment with a compound which alters its biotransformation (ie, phenobarbital, an inducer of microsomal metabolism), (b) CP was given after previous treatment with CP (which inhibits microsomal metablism), or (c) CP was given with competitive substrates of aldehyde oxidase or dehydrogenase (glyceraldehyde, chloral hydrate, and disulfiram). Results obtained in animals or in the perfused liver will be discussed. The significance of this modified CP metabolism in influencing its cytotoxic effect will be discussed and correlations between drug levels and activity will be presented.
D000818:Animals; D002279:Carcinoma 256, Walker / Q000378:metabolism; D002697:Chloral Hydrate / Q000494:pharmacology; D003520:Cyclophosphamide / Q000097:blood / Q000378:metabolism* / Q000494:pharmacology; D004221:Disulfiram / Q000494:pharmacology; D004347:Drug Interactions; D005985:Glyceraldehyde / Q000494:pharmacology; D006207:Half-Life; D066298:In Vitro Techniques; D008099:Liver / Q000378:metabolism; D008657:Metabolic Clearance Rate; D051379:Mice; D008810:Mice, Inbred C57BL; D009374:Neoplasms, Experimental / Q000188:drug therapy; D010477:Perfusion; D010634:Phenobarbital / Q000494:pharmacology; D012513:Sarcoma, Experimental / Q000378:metabolism
D005985:Glyceraldehyde; D002697:Chloral Hydrate; D003520:Cyclophosphamide; D004221:Disulfiram; D010634:Phenobarbital